The δ-opioid receptor agonist SNC80 (+)-4-[α(R)-α-[(2S, 5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-(3-methoxybenzyl)-N,N-diethylbenzamide] synergistically enhances the locomotor-activating effects of some psychomotor stimulants, but not direct dopamine agonists, in rats

Emily M. Jutkiewicz, Michelle G. Baladi, John E. Folk, Kenner C. Rice, James H. Woods

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The nonpeptidic δ-opioid agonist SNC80 [(+)-4-[α(R)-α- [(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-(3-methoxybenzyl)-N, N-diethylbenzamide] produces many stimulant-like behavioral effects in rodents and monkeys, such as locomotor stimulation, generalization to cocaine in discrimination procedures, and antiparkinsonian effects. Tolerance to the locomotor-stimulating effects of SNC80 develops after a single administration of SNC80 in rats; it is not known whether cross-tolerance develops to the effects of other stimulant compounds. In the initial studies to determine whether SNC80 produced cross-tolerance to other stimulant compounds, it was discovered that amphetamine-stimulated locomotor activity was greatly enhanced in SNC80-pretreated rats. This study evaluated acute cross-tolerance between δ-opioid agonists and other locomotor-stimulating drugs. Locomotor activity was measured in male Sprague-Dawley rats implanted with radiotransmitters, and activity levels were recorded in the home cage environment. Three-hour SNC80 pretreatment produced tolerance to further δ-opioid receptor stimulation but also augmented greatly amphetamine-stimulated locomotor activity in a dose-dependent manner. Pretreatments with other δ-opioid agonists, (+)BW373U86 [(+)-4-[α(R)-α-[(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl] -3-hydroxybenzyl]-N,N-diethylbenzamide] and oxymorphindole (17-methyl-6,7- dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2′,3′-indolomorphinan), also modified amphetamine-induced activity levels. SNC80 pretreatment enhanced the stimulatory effects of the dopamine/norepinephrine transporter ligands cocaine and nomifensine (1,2,3,4-tetrahydro-2-methyl-4-phenyl-8-isoquinolinanmine maleate salt), but not the direct dopamine receptor agonists SKF81297 [R-(+)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide] and quinpirole [trans-(-)-(4αR)-4,4a, 5,6,7,8,8a,9- octahydro-5-propyl-1H-pyrazolo[3,4-g] quinoline monohydrochloride]. In conclusion, SNC80 enhanced the locomotor-stimulating effects of monoamine transporter ligands suggesting that δ-opioid receptor activation might alter the functional activity of monoamine transporters or presynaptic monoamine terminals.

Original languageEnglish (US)
Pages (from-to)714-724
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume324
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'The δ-opioid receptor agonist SNC80 (+)-4-[α(R)-α-[(2S, 5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-(3-methoxybenzyl)-N,N-diethylbenzamide] synergistically enhances the locomotor-activating effects of some psychomotor stimulants, but not direct dopamine agonists, in rats'. Together they form a unique fingerprint.

Cite this